Introduction: Invasive Candida infections cause significant mortality and morbidity worldwide. Information on recent trends in species distribution and antifungal resistance in local settings is essential. Methodology: Yeast isolates identified through standard culture methods throughout 2014 and 2015 from Hospital Ampang, Malaysia were retrospectively studied. The antifungal susceptibility of Candida species was determined using colorimetric broth microdilution method and MIC values interpreted according to CLSI breakpoints. Results: Out of all the 149 yeast cultures collected, most were from blood (55.7%) and respiratory specimens (33.6%). Candida tropicalis was the most common (28.9%), followed by C. albicans (26.2%), C. parapsilosis (15.4%), C. glabrata (14.1%), Crytococcus neoformans (6.7%), Trichosporon asahi (3.4%), C. krusei (2.0%), C. famata, C. rugose, C. guilliermondii, C. dublinensis and Trichosporon spp. (0.7% each). Occurrence of C. tropicalis in candidaemia cases was significantly associated to presence of an underlying haematological disorder, while C. albicans isolates in blood were significantly found in absence of such disorders. The four most common Candida species isolated showed high susceptibility to amphotericin B (100%), anidulafungin (100%), micafungin (100%), caspofungin (98.4%), flucytosine (98.4%) and voriconazole (84.1%). However, drug susceptibility to itraconazole and fluconazole was comparatively lower (57.9% and 72.2%, respectively). C. glabrata and C. tropicalis were the least susceptible to these azoles. Conclusion: Prevalence of the high number of non-albicans Candida species with slight predominance of C. tropicalis over C. albicans was observed. Low susceptibility to itraconazole among C. glabrata and C. tropicalis isolates and to fluconazole among C. glabrata isolates warrants for continued surveillance to monitor emerging antifungal resistance.
Introduction
The incidence of invasive yeast infections worldwide continues to rise mainly due to increased use of immunosuppressive therapy and invasive devices [1] . Candida spp. are the most common cause of invasive yeast infections yet alone the most common cause of fungal infections [2] . Candida spp. are part of the normal flora of healthy hosts that are responsible for various superficial and systemic, opportunistic infections [3] . Although Candida albicans remains the major cause of invasive candidiasis, increasing trends in infections caused by non-albicans species have been observed in recent years worldwide [4] [5] [6] including Malaysia [7] [8] [9] . Next to candidiasis, other yeast infections are usually caused by Cryptococcus neoformans followed by the less common Trichosporon spp., Rhodotorula spp and others [3;6;10] .
Invasive candidiasis is associated with significant morbidity and mortality and therefore appropriate and timely antifungal therapy is essential [11] . The Infectious Diseases Society of America (IDSA) recommends the newest class of antifungal agents, the echinocandins i.e. caspofungin, micafungin or anidulafungin as initial therapy for candidaemia in both neutropenic and non-neutropenic patients [12] . However, fluconazole is still widely used due to its low cost and availability for both parenteral and enteral administration. Reduced susceptibility of Candida, especially non-albicans species, to fluconazole and the overall cost effectiveness with echinocandins, especially in the critically ill patients, favours echinocandins [13;14] . While fluconazole resistance differs between countries, resistance to echinocandins has also emerged in some countries [15] 
Yeast Isolation and Identification
Data on yeast cultures obtained from normally sterile sites (i.e. blood; respiratory, such as bronchoalveolar lavage and nasopharyngeal aspirate; tissue; cerebrospinal fluid; bone; peritoneal fluid and bile) and detailed information of the patients were gathered from the Laboratory and Hospital Information System. Repetitive cultures from the same patient that yielded same yeast species (within three months) were excluded. The isolation and identification of fungi were performed using standard methods in the microbiology laboratory within the hospital; all specimens were inoculated on Sabouraud's dextrose agar, brain heart infusion agar and mycosel agar and incubated at 30⁰C for 48 hours. Identification was done by germ tube technique, inoculation on chromogenic agar and biochemical identification tests. Germ tube test was performed by inoculating isolated yeast cells into serum and incubating at 37⁰C for 2 hours. Yeast isolates were subcultured on chromogenic Candida medium (Oxoid, Basingstoke, UK) at 37⁰C for 48 hours to distinguish Candida species based on specific colony colours produced by the chromogenic substrates in the medium. All isolates were then subjected to the API 20C AUX biochemical identification kit (BioMérieux, Marcy I'Etoile, France) for confirmatory identification of the yeast isolates.
Antifungal Susceptibility Testing
Antifungal susceptibility test was performed at the reference laboratory in Hospital Sungai Buloh, Selangor, Malaysia using colorimetric microdilution susceptibility test (Sensititre YeastOne ) by Trek Diagnostic System (Cleveland, USA). Briefly, a 20µL volume of suspension of 24-hour yeast colony adjusted to 0.5 Mc Farland density was transferred to 11mL of YeastOne inoculum broth to obtain a final density of 1.5 -8.0 ×10 3 CFU/mL. A 100µl volume of this mixture was transferred into each well of the Sensititre plate containing serial dilutions of amphotericin B, fluconazole, itraconazole, voriconazole, anidulafungin, micafungin, caspofungin and 5-flucytosine. The wells were covered using an adhesive seal and incubated at 35ºC in a non-CO2 incubator for 24 hours.
The plate was then read under normal laboratory lighting using a reading mirror that displayed the underside of the wells. The MIC was recorded as the lowest concentration of antifungal agent inhibiting the development of colour change from the initial blue to red or purple (indicating yeast growth). MIC results were interpreted according to species-specific clinical breakpoints established by Clinical and Laboratory Standards Institute (CLSI) [17] . MIC50 and MIC90 values, defined as the concentration of antifungal agent that inhibited 50% and 90% of the isolates, respectively, were determined.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics version 24.0 (IBM Corporation, New York, USA). Pearson's Chi-squared test was performed to investigate statistical significance between variables. All statistical analysis were two tailed and a p-value < 0.05 in a two-sided test was considered significant.
Results
A total of 149 cases of yeasts infection were identified during this 2-year-period, 85 of which were from male patients (57%) and 64 from female patients (43%). Only 53 of these patients had an underlying haematological disorder (35.5%). The underlying haematological disorders were lymphoma (17.4%), acute myeloid leukaemia (10.7%), acute lymphoblastic leukaemia (3.4%), chronic lymphocytic leukaemia (2.0%), multiple myeloma (1.3%) and aplastic anaemia (0.7%). Most of the isolates obtained were from blood (55.7%) and respiratory (33.6%) specimens. Respiratory specimens included broncho-alveolar lavage and nasopharyngeal aspirate. C. tropicalis was the yeast most commonly isolated from blood (33.7% of all blood isolates), while C. albicans predominated in the respiratory specimens (36% of all respiratory isolates). The distribution of the different Candida species isolated from blood according to age group and presence of an underlying haematological disorder is shown in Table 2 . While the 73 candidaemia isolates included seven from infants, the most number of isolates were equally found in the 40-59 and 60 & above age groups. No significant association was found between patient age group and species of Candida. However, the occurrence of C. tropicalis in candidaemia cases was significantly associated to presence of an underlying haematological disorder (p = 0.002). C. albicans on the other hand was mostly found in the absence of haematological disorders (p = 0.009).
The antifungal susceptibility results of the four most commonly isolated Candida species are summarised in Table 3. Table 4 summarizes the MIC ranges as well as MIC50 and MIC90 values of the eight antifungal drugs tested against these Candida species. Overall, high susceptibility to amphotericin B (100%), anidulafungin (100%), micafungin (100%), caspofungin (98.4%) and flucytosine (98.4%) was observed. C. albicans and C. parapsilosis also showed high susceptibility to the three azoles i.e. voriconazole, itraconazole and fluconazole. C. tropicalis however had reduced susceptibility to voriconazole (76.7%), itraconazole (39.5%) and fluconazole (76.7%). C. glabrata on the other hand, although was highly susceptible to voriconazole (81.0%), was only 9.5% susceptible to itraconazole and fluconazole. [18] . In the present study, non-albicans Candida accounted to 70.7% of the total Candida isolates and 76.7 % of the candidaemia causing isolates obtained throughout year 2014 and 2015. The incidence of non-albicans Candida worldwide is generally observed to be increasing. Still, the proportion of non-albicans Candida among Candida species in hospital-based studies done in various parts of the world seem to largely vary from 18.3% to 83.0% [19] . This variability between different geographical regions is caused by several factors, mostly due to different antifungal treatment practices, use of indwelling catheters, patient demographic features and chronic underlying diseases [18] .
In this study, C. tropicalis was found to be the most common yeast isolated, specifically in blood specimens. The organism outnumbered C. albicans by 2.7%, a trend not observed before in other Malaysian studies. A study on candidaemia cases from 2005 to 2006 at another tertiary hospital in Malaysia by Tzar and Shamim [7] also found C. tropicalis to be the most frequent non-albicans Candida, however C. albicans isolates were higher by 8%. Similarly, Ng and colleagues [8] also found C. tropicalis to be the most common Candida species isolated from blood next to C. albicans, among isolates from various specimens obtained between 2000 and 2013. C. tropicalis is indeed the leading non-albicans species in Asia and more so in tropical areas [20] , when compared to other regions such as Europe, UK and USA [19] . Increase in number of C. glabrata isolates on the other hand have been reported in Europe and USA, owing to the extensive use of fluconazole as prophylaxis and treatment [19] .
In this study, blood and respiratory cultures accounted for 55.7% and 33.6%, respectively of all yeast isolates. It is important to note that isolation of Candida from respiratory tract should not be considered as a marker of lung infection. A study reported that no cases of Candida pneumonia was identified among 135 autopsies with histopathological evidence of bacterial infection and high rate of Candida isolation from endotracheal aspirate and/ or bronchalveolar lavage [21] .
Although not significant, most (65.1%) of the C. tropicalis isolates found herein, were from blood specimens, a trend also reported elsewhere [6] . On the other hand, more than half of the C. albicans isolates (56.4%) were obtained from non-blood samples. C. tropicalis isolation from blood specimens was found to be significantly associated to an underlying haematological disorder, while C. albicans was significantly negatively related. Similarly, a study revealed significantly lower occurrence of C. albicans in patients with haematological disorders when compared to patients with solid tumours; while nonalbicans Candida, namely C. krusei and C. glabrata were more prevalent among the former [22] .
This study is the first of such, reporting on yeast isolates from Hospital Ampang, Malaysia. The hospital being a national reference centre for haematological disorders in Malaysia, and significant association between C. tropicalis isolation and underlying haematological disorders (and vice versa with C. albicans) justifies the increased incidence of C. tropicalis as compared to C. albicans noted herein.
Risk factors of invasive Candida infections vary between species. Risk factors for C. tropicalis includes older age, cancer, neutropenia and presence of biofilms in urinary catheters [23] . Duration of central venous catheter use, use of fluconazole, gastrointestinal surgery, older age, intravenous drug use and glucocorticoid therapy are significant risk factors for C. glabrata and C. krusei; while younger age and prior exposure to echinocandin antifungals have been associated with C. parapsilosis infections [18] . Information on recent trends in antifungal susceptibility patterns is important in determining best prophylactic and therapeutic strategies. In the present study, the antifungal susceptibility pattern of the four most common Candida spp. isolated herein were analysed. All the isolates were either completely and/ or highly susceptible to amphotericin B, the echinocandins and flucytosine. Antifungal resistance among C. albicans is generally uncommon [12] and the same was noted herein. C. parapsilosis was also highly susceptible to all antifungals tested including the azoles. Relatively higher MIC90 values for the echinocandins were noted in C. parapsilosis. Four of the 23 C. parapsilosis isolates had an MIC value of 2µg/mL for anidulafungin and micafungin. Although resistance to echinocandins is rare among Candida species, C. parapsilosis is known to be innately less active to the echinocandins [12; 24] .
Only 9.5% of C. glabrata isolates were susceptible to fluconazole and itraconazole. This is a huge difference compared to an 83.4% (n=12; year 2006-2008) susceptibility of C. glabrata to these azoles reported by Amran and colleagues at another tertiary hospital in Malaysia [9] . However, they also noted that MIC90 value of itraconazole was comparatively high for C. glabrata. Although only 9.5% of C. glabrata isolates were susceptible to fluconazole and itraconazole, the resistance level was about similar to C. tropicalis and C. albicans because a large percentage of C. glabrata isolates were susceptible-dose dependant (SDD) to these two drugs (42.9% and 61.9% respectively). The low susceptibility of C. glabrata to fluconazole and itraconazole is in accordance to findings from other tertiary hospitals in Malaysia [7; 16] . Furthermore, the total susceptibility of all candidaemia isolates to itraconazole was reported to be as low as 40% (of total 50 Candida isolates) by Tzar and Shamim [7] . Santhanam and colleagues reported a susceptibility of 56.1% among a total of 82 Candida isolates obtained in 2009 at Hospital Kuala Lumpur, Malaysia, further confirming this low susceptibility of Candida species to itraconazole as a recent trend in Malaysia [16] . In agreement to that, the present study found the overall susceptibility of the four most common Candida species to itraconazole to be 57.9%. Herein, a slightly low susceptibility to fluconazole (72.2%) was also noted, as compared to 90% and 82.9% reported by the other two studies, respectively [7; 16] . High reduction in fluconazole susceptibility rate over the years among C. glabrata isolates is not uncommon [20; 25] owing to long term and routine use of the drug. It is hence important to monitor the resistance pattern in Malaysia to provide useful information on therapeutic approaches.
Voriconazole was the most active azole against C. glabrata, as also noted in another study [6] . Due to increase in azole resistance among C. glabrata isolates worldwide, antifungal susceptibility testing is highly recommended prior to treatment of this species with azoles [12] . Next to C. glabrata, C. tropicalis showed lowest susceptibility to the azole group of antibiotics, especially itraconazole. This is not encouraging since the prevalence of both species accounts to about 43% of the total isolates. Furthermore these two species are reportedly more virulent than C. albicans [22] .
Conclusions
The yeast isolates, mainly being Candida spp, isolated in the year 2014 and 2015 at Hospital Ampang in Selangor, Malaysia, were predominated by nonalbicans Candida species. C. tropicalis was the most common species isolated and more so in blood samples. The antifungal resistance observed in the present study was mainly restricted to the azoles. All Candida species were highly susceptible to amphotericin B, the echinocandins and flucytosine. Lowest drug susceptibility was noted to itraconazole especially among C. glabrata and C. tropicalis isolates and to fluconazole among C. glabrata isolates. These findings emphasize the trend seen worldwide on increasing resistance to the azoles especially among the nonalbicans Candida species. The opposite correlation seen in the present study between prevalence of C. tropicalis and C. albicans with underlying haematological disorders may have caused a higher incidence of azole-resistance in this clinical setting which warrants for a multicenter study in the future, for confirmation.
